Add Yahoo as a preferred source to see more of our stories on Google. September and October 2025 have proven busy for multiple sclerosis (MS) professionals, as many gathered at three major conferences ...
Rituximab (Rituxan) provides consistently better relapse outcomes than natalizumab (Tysabri) in patients with multiple sclerosis (MS), new research suggests. Findings from a real-world "comparative ...
A simple algorithm to aid in the selection of appropriate disease modifying therapies (DMTs) reduces racial disparities in patients with relapsing multiple sclerosis (MS), early new research showed.
TOKYO--(BUSINESS WIRE)-- Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and ...
Please provide your email address to receive an email when new articles are posted on . Risk of treatment discontinuation at 2 years was six times higher with moderately effective therapies. Highly ...
In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...
Starting high-efficacy monoclonal antibody therapy during childhood reduced long-term disability in pediatric-onset multiple sclerosis (MS), registry data suggested. Among 282 patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results